VERU INC. - COMMON STOCK

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

18 يونيو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders

17 يونيو 2024 16:45:00 بحسب Nasdaq GlobeNewswire

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

10 يونيو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Present at the Jefferies Global Healthcare Conference

22 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

15 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

14 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

08 مايو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Veru to Present at the GLP-1 Based Therapeutics Summit

02 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

01 مايو 2024 08:30:37 بحسب Nasdaq GlobeNewswire

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

30 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

25 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Announces Date of 2024 Annual Meeting of Shareholders

01 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Veru Reschedules Annual Meeting of Shareholders

22 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

12 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

27 فبراير 2024 19:15:00 بحسب Nasdaq GlobeNewswire

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

20 فبراير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru Reports Fiscal 2024 First Quarter Financial Highlights

08 فبراير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

06 فبراير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

31 يناير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

25 يناير 2024 08:30:00 بحسب Nasdaq GlobeNewswire